Hessam Schapoor, Sand Michael, Meier Nina Mareike, Gambichler Thilo, Scholl Lisa, Bechara Falk G
Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany.
Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany.
J Dermatol Sci. 2016 Nov;84(2):197-202. doi: 10.1016/j.jdermsci.2016.08.010. Epub 2016 Aug 10.
Hidradenitis suppurativa (HS) is often a therapeutic challenge with relapses and chronicity which can severely impact patients' quality of life.
To evaluate the efficacy of anti-inflammatory oral zinc gluconate, 90mg/day, combined with topical triclosan, 2% twice daily.
We retrospectively evaluated the medical records of HS patients in our HS Center of the Department of Dermatology, Venereology, and Allergology, Ruhr-University Bochum, regarding change of disease severity and quality of life. Secondary outcome measures were the number of nodules and fistulas, the number of boils or flair-ups, and the intensity of pain.
Sixty-six patients in Hurley stage I and II were included. After 3 months of combination therapy, the modified HS Score and the Dermatology Life Quality Index improved significantly (p<0.0001 and p=0.0386, respectively). The number of inflammatory nodules, new boils or flare-ups, and erythema scores decreased significantly. Fistula count and the visual analogue scale score showed no significant difference. Side-effects (mostly abdominal pain and nausea) were reported by 12 (22.2%) patients.
The combination therapy of zinc gluconate and topical triclosan can be considered as an anti-inflammatory treatment for HS patients in Hurley stage I and initial Hurley stage II.
化脓性汗腺炎(HS)通常是一种治疗难题,具有复发和慢性病程,会严重影响患者的生活质量。
评估每日90毫克口服葡萄糖酸锌联合每日两次外用2%三氯生的抗炎疗效。
我们回顾性评估了德国波鸿鲁尔大学皮肤科、性病科和变态反应科HS中心的HS患者病历,以了解疾病严重程度和生活质量的变化。次要观察指标包括结节和瘘管数量、疖子或炎症发作次数以及疼痛强度。
纳入了66例Hurley I期和II期患者。联合治疗3个月后,改良HS评分和皮肤病生活质量指数显著改善(分别为p<0.0001和p=0.0386)。炎性结节数量、新出现的疖子或炎症发作次数以及红斑评分显著降低。瘘管数量和视觉模拟量表评分无显著差异。12例(22.2%)患者报告有副作用(主要是腹痛和恶心)。
葡萄糖酸锌和外用三氯生联合治疗可被视为Hurley I期和Hurley II期初期HS患者的一种抗炎治疗方法。